Nov 2, 2023 · Background: RO7283420 (RG6007) is a 2+1 TCR-like (TCR-L) T-cell bispecific (TCB) antibody targeting CD3 and the RMFPNAPYL peptide of Wilms Tumor 1 (WT1) protein presented by the major histocompatibility complex-I HLA-A*02 on acute myeloid leukemia (AML) blasts and other antigen presenting cells.

Upon administration, anti-HLA-A2-WT1/anti-CD3 T-cell engaging bispecific antibody RO7283420 simultaneously binds to both CD3 on cytotoxic T lymphocytes (CTLs) and the HLA-A2 WT1 complex found on WT1-expressing tumor cells.

Dec 23, 2021 · By simultaneously targeting CD3 and WT1, the authors demonstrate that WT1-TCB results in T-cell activation and killing of both AML cell lines and primary tumors in a WT1 and HLA-A2 dependent fashion with minimal effect on normal CD34 + hematopoietic cells. 1

Nov 10, 2023 · Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

In this study, we report the design, optimization and characterization of a DuetMab based CD3 T cell engager, named T cell engager DuetMab (TED), which can target tumor cells expressing a low copy number of TAA-derived pMHCs.

Mar 22, 2024 · Here, we described the development of WT1-TOPAbody, a novel tri-specific T cell engager (TCE), that activated T cells by both CD3 and 4-1BB signaling upon recognition of WT1 in the context of HLA-A02, leading to superior anti-tumor efficacy.

Jun 19, 2015 · In this study, we used enrichment techniques based on pHLAI tetramer staining and the up-regulation of activation markers to characterize the entire WT1-specific T-cell repertoire functionally and phenotypically in a comprehensive and highly sensitive manner.

May 3, 2021 · A BiTE molecule derived from ESK1, a TCR-mimic monoclonal antibody, can specifically bind WT1 + cells from HLA-A*02:01 + AML cell lines and CD3 + T cells. Its efficacy of killing WT1 + AML cells has been proved by experiments in vitro and in mouse models [ 97 ].

In this study, CD3 + T cells from healthy donor peripheral blood were stimulated with the WT1 peptide or mixed BCR-ABL peptides in the presence or absence of IL-2 and IL-7. The distribution of the TCR Vβ repertoire was analyzed after different stimulations.

Sep 21, 2015 · Here we describe a bispecific T-cell engager (BiTE) antibody derived from a T-cell receptor (TCR)-mimic monoclonal antibody (mAb) ESK1, which binds a peptide derived from the intracellular...